Pharm
Indinavir
search
Indinavir
, Crixivan
See Also
Anti-Retroviral Therapy
Protease Inhibitor
Indications
HIV Infection
(as part of combination therapy)
Has been replaced by newer
Protease Inhibitor
s with fewer adverse effects
Among the first
Protease Inhibitor
s for HIV (FDA approved in 1996)
Mechanism
See
Protease Inhibitor
Efficacy
When originally studied in the 1990s, Indinavir was very effective in combination with
Zidovudine
(AZT)
Newer
Protease Inhibitor
s are combined with boosters (e.g.
Ritonavir
,
Cobicistat
) and are used with other
Antiretroviral
s
Medications
Capsules: 100, 200, 400 mg
Dosing
Adults (as part of combination therapy with other
Antiretroviral
s)
Indinavir 800 mg orally three times daily
Indications to reduce dose to 600 mg orally three times daily
Delavirdine
Itraconazole
or
Ketoconazole
Hepatic insufficiency
Take on empty
Stomach
One hour before or 2 hours after a meal
Concurrent food reduces concentration up to 80%
Drink at least 1.5 Liters (50 oz) liquid per day
Drink 150 ml water per hour for 3 hours after dose
Avoids
Nephrolithiasis
and
Interstitial Nephritis
Adverse Effects
See
Protease Inhibitor
for adverse effects attributed to the class
Well tolerated
Indirect Bilirubin
(elevation in 10% of patients)
Nephrolithiasis
in 2-3% of patients
Hyperglycemia
Renal Insufficiency
Alopecia
Dry Skin
Xerostomia
Paronychia
Gallstone
s
Drug Interactions
See
Protease Inhibitor
Drug Interaction
s are common with
Protease Inhibitor
s
Protease Inhibitor
s cause the most
Drug Interaction
s of all
Antiretroviral
s
Use formal
Drug Interaction
applications when prescribing
St. John's Wort
May reduce Indinavir concentrations by 80%
Piscitelli (2000) Lancet 355:547-8 [PubMed]
Rifabutin
Decrease
Rifabutin
dose to 50% AND
Increase Indinavir 1000 mg orally three times daily
Medications contraindicated with Indinavir (a strong
CYP3A4
Inhibitor)
Alfuzosin
Amiodarone
Ergot alkaloids (e.g.
Ergonovine
,
Ergotamine
)
Pimozide
High dose
Sildenafil
(Revatio)
Sedative Hypnotic
s (oral
Midazolam
,
Triazolam
,
Alprazolam
)
Safety
Avoid in
Lactation
(as with other
Protease Inhibitor
s)
Pregnancy Category C
Risk of perinatal
Hyperbilirubinemia
Resources
Indinavir (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=702727cb-3eff-425b-9573-031332849430
References
(1998) Med Lett Drugs Ther 40(1041):115 [PubMed]
(2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]
Type your search phrase here